Stan Berenshteyn
Stock Analyst at Wells Fargo
(0.85)
# 3,370
Out of 4,670 analysts
54
Total ratings
46.67%
Success rate
-16.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DOCS Doximity | Upgrades: Equal-Weight | $19 → $41 | $48.20 | -14.94% | 8 | Nov 8, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $30 → $41 | $45.69 | -10.26% | 11 | Oct 14, 2024 | |
| ACCD Accolade | Maintains: Equal-Weight | $7 → $6 | $3.70 | +62.16% | 10 | Oct 11, 2024 | |
| AMWL American Well | Maintains: Equal-Weight | $40 → $15 | $8.10 | +85.19% | 2 | Aug 6, 2024 | |
| HQY HealthEquity | Maintains: Overweight | $107 → $110 | $104.25 | +5.52% | 8 | Jun 20, 2024 | |
| HCAT Health Catalyst | Maintains: Overweight | $14 → $13 | $8.13 | +59.90% | 4 | May 10, 2024 | |
| GDRX GoodRx Holdings | Upgrades: Overweight | $10 | $4.90 | +104.08% | 6 | Mar 25, 2024 | |
| VEEV Veeva Systems | Upgrades: Overweight | $211 → $229 | $216.58 | +5.73% | 3 | Oct 25, 2023 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $28 → $23 | $10.62 | +116.57% | 2 | Mar 6, 2023 |
Doximity
Nov 8, 2024
Upgrades: Equal-Weight
Price Target: $19 → $41
Current: $48.20
Upside: -14.94%
Omnicell
Oct 14, 2024
Maintains: Equal-Weight
Price Target: $30 → $41
Current: $45.69
Upside: -10.26%
Accolade
Oct 11, 2024
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.70
Upside: +62.16%
American Well
Aug 6, 2024
Maintains: Equal-Weight
Price Target: $40 → $15
Current: $8.10
Upside: +85.19%
HealthEquity
Jun 20, 2024
Maintains: Overweight
Price Target: $107 → $110
Current: $104.25
Upside: +5.52%
Health Catalyst
May 10, 2024
Maintains: Overweight
Price Target: $14 → $13
Current: $8.13
Upside: +59.90%
GoodRx Holdings
Mar 25, 2024
Upgrades: Overweight
Price Target: $10
Current: $4.90
Upside: +104.08%
Veeva Systems
Oct 25, 2023
Upgrades: Overweight
Price Target: $211 → $229
Current: $216.58
Upside: +5.73%
Teladoc Health
Mar 6, 2023
Maintains: Equal-Weight
Price Target: $28 → $23
Current: $10.62
Upside: +116.57%